aid: dermbiont
name: DermBiont
description: 'DermBiont, Inc. is a Boston, Massachusetts clinical-stage dermatology
  therapeutics company founded in 2017 that develops targeted topical treatments addressing
  the root cause of skin disease rather than its symptoms. Its lead program SM-030
  is a first-in-class topical PKC-beta inhibitor in development for melasma and other
  hyperpigmentation disorders of the skin, targeting excess melanin production; earlier
  programs included SM-020 for seborrheic keratosis and the live-bacterial DBI-001
  and DBI-002 candidates for atopic dermatitis, tinea pedis and onychomycosis. The
  company describes an in-house discovery platform for microbiome-based therapeutics
  built on terabytes of DNA sequencing data from human skin samples across healthy
  individuals and patients, paired with a proprietary computational biology platform
  that identifies functions gained and lost by the skin microbiome. That computational
  platform is internal research tooling, not a product: DermBiont sells drug candidates
  and partnering opportunities, publishes no developer program, no public API, no SDK
  and no machine-readable API contract of any kind, and its website is a Squarespace-hosted
  corporate site.'
image: https://static1.squarespace.com/static/5be33300f93fd46b40da5761/t/629e316bea93f12ec9cc272d/1654534507403/DM-main-logo.png?format=1500w
url: https://raw.githubusercontent.com/api-evangelist/dermbiont/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Dermatology
- Therapeutics
- Skin Microbiome
- Microbiome
- Drug Discovery
- Clinical Stage
- Life Sciences
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/dermbiont-domain-security.yml
- type: Website
  url: https://www.dermbiont.com/
- type: About
  url: https://www.dermbiont.com/overview
- type: Product
  url: https://www.dermbiont.com/platform
- type: Platform
  url: https://www.dermbiont.com/dermatology-platform
- type: Pipeline
  url: https://www.dermbiont.com/pipeline
- type: Leadership
  url: https://www.dermbiont.com/leadership
- type: Contact
  url: https://www.dermbiont.com/contact-us
- type: Support
  url: https://www.dermbiont.com/contact-us
- type: LinkedIn
  url: https://www.linkedin.com/company/dermbiont
- type: Crunchbase
  url: https://www.crunchbase.com/organization/dermbiont
- type: LLMsTxt
  url: llms/dermbiont-llms.txt

x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 3
  pass: local-v1

x-coverage:
  state: none
  reason: not-a-software-company
  detail: DermBiont is a clinical-stage dermatology drug developer whose only product
    is the SM-030 topical candidate; its sole web property is a 30-page Squarespace
    corporate site with no developer, docs or API section anywhere in its sitemap,
    every OpenAPI, GraphQL, llms.txt and .well-known path returns 404, api.dermbiont.com
    does not resolve, and no GitHub organization or first-party package exists on any
    public registry.
  evidence:
  - url: https://www.dermbiont.com/openapi.json
    status: 404
  - url: https://www.dermbiont.com/graphql
    status: 404
  - url: https://www.dermbiont.com/llms.txt
    status: 404
  - url: https://www.dermbiont.com/.well-known/agent-card.json
    status: 404
  - url: https://www.dermbiont.com/.well-known/agent.json
    status: 404
  - url: https://www.dermbiont.com/.well-known/security.txt
    status: 404
  - url: https://api.github.com/orgs/dermbiont
    status: 404
  - url: https://www.dermbiont.com/sitemap.xml
    status: 200
  checked: '2026-08-12'